Patents Represented by Attorney Michael G. Smith
-
Patent number: 8349852Abstract: There is described a new polymorphic form of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and a method of preparing it.Type: GrantFiled: January 6, 2010Date of Patent: January 8, 2013Assignee: Novartis AGInventors: Weichun Chen, Hong-Yong Kim, Jessica Liang, Michael Mutz, Mahavir Prashad, Christopher Towler, Ruoqiu Wu
-
Patent number: 8329732Abstract: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: GrantFiled: August 31, 2009Date of Patent: December 11, 2012Assignee: Novartis AGInventors: Matthew T. Burger, Wooseok Han, Jiong Lan, Gisele Nishiguchi
-
Patent number: 8318791Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.Type: GrantFiled: June 5, 2009Date of Patent: November 27, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
-
Patent number: 8293769Abstract: Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.Type: GrantFiled: May 20, 2008Date of Patent: October 23, 2012Assignee: Novartis AGInventors: Simon C. Ng, Keith B. Pfister, Martin Sendzik, James Sutton, Allan S. Wagman, Marion Wiesmann
-
Patent number: 8273900Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.Type: GrantFiled: July 31, 2009Date of Patent: September 25, 2012Assignee: Novartis AGInventors: David Beattie, Anny-Odile Colson, Andrew James Culshaw, Lisa Sharp, Emily Stanley, Lilya Sviridenko
-
Patent number: 8268834Abstract: The present invention concerns a compound of formula (I) or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, wherein the groups R1, R2, Ar?, A and Y are defined in the description, to compositions and use of the compounds in the treatment of inflammatory and allergic conditions.Type: GrantFiled: March 4, 2009Date of Patent: September 18, 2012Assignee: Novartis AGInventors: Ian Bruce, Emma Budd, Lee Edwards, Catherine Howsham
-
Patent number: 8252832Abstract: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.Type: GrantFiled: November 25, 2008Date of Patent: August 28, 2012Assignee: Novartis AGInventors: Tinya Abrams, Paul Barsanti, David Duhl, Michel Faure, Paul A. Renhowe, Annette Olga Walter
-
Patent number: 8242260Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.Type: GrantFiled: August 24, 2010Date of Patent: August 14, 2012Assignee: Novartis AGInventors: Abran Q. Costales, Shenlin Huang, Jeff Xianming Jin, Zuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew, Qiong Zhang
-
Patent number: 8173689Abstract: Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.Type: GrantFiled: May 8, 2009Date of Patent: May 8, 2012Assignee: Novartis AGInventors: James C. Sutton, Marion Wiesmann
-
Patent number: 8168794Abstract: The present invention relates to new compounds of Formulas I and II, their tautomers, stereoisomers and polymorphs, and pharmaceutically acceptable salts, esters, metabolites or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the inhibition of Pim kinase activity and/or the prophylaxis or treatment of cancer.Type: GrantFiled: February 26, 2009Date of Patent: May 1, 2012Assignee: Novartis AGInventors: Matthew Burger, Jiong Lan, Mika Lindvall, Gisele Nishiguchi, Michelle Tetalman
-
Patent number: 8163785Abstract: There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives of Formula I: which are useful as corticotropin releasing factor (CRF) receptor antagonists and as pharmaceuticals.Type: GrantFiled: January 31, 2011Date of Patent: April 24, 2012Assignee: Novartis AGInventors: Nicholas James Devereux, Jeffrey McKenna
-
Patent number: 8156945Abstract: Systems, methods and apparatus are provided through which in some implementations an abrasive exterior is attached to a body about obtuse to a right-angle of a trapezoid geometry of the body. In some implementations, the body includes a pocket along a longitudinal axis of the body and in some implementations the body includes a groove along a lateral axis.Type: GrantFiled: December 9, 2009Date of Patent: April 17, 2012Inventors: Karmen C. Hart, Carolyn L. Jones
-
Patent number: 8129358Abstract: Disclosed are new substituted pyrazole and triazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof:Type: GrantFiled: November 8, 2007Date of Patent: March 6, 2012Assignee: Novartis AGInventors: Yi Xia, Kris G. Mendenhall, Paul A. Barsanti, Annette O. Walter, David Duhl, Paul A. Renhowe
-
Patent number: 8129394Abstract: Novel imidazole compounds of the general formula are disclosed, wherein R1 and R2 comprise heteroaryl groups. These compounds and compositions containing them are useful in methods to treat Raf kinase-mediated disorders such as cancer.Type: GrantFiled: March 19, 2009Date of Patent: March 6, 2012Assignee: Novartis AGInventors: Zilin Hunag, Jeff Jin, Timothy Machajewski, William R. Antonios-McCrea, Maureen McKenna, Daniel Poon, Paul A. Renhowe, Martin Sendzik, Cynthia Shafer, Aaron Smith, Yongjin Xu, Qiong Zhang, Zheng Chen
-
Patent number: 8098060Abstract: Systems, methods and apparatus are provided through which in some implementations determine the amplitude of an amplitude modulated signal, modulated by the position of an object being sensed. In some aspects, the apparatus accepts an excitation signal and the amplitude modulated signal and divides the amplitude modulated by the excitation signal to produce an output signal that is proportional to the position of the object being sensed. In other aspects, the division is performed only when the excitation signal is non-zero, such as close to the peaks in the excitation signal. In other aspects, the excitation signal and amplitude modulated signal are degraded due to an air gap and the degraded signals are used to correct for amplitude fluctuations due to the air gap, and produce an output signal, tolerant of the air gaps, that is proportional to the position of the object being sensed.Type: GrantFiled: July 15, 2008Date of Patent: January 17, 2012Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space AdministrationInventors: David E. Howard, Dean C. Alhorn, Dennis A. Smith, Kenneth R. Dutton
-
Patent number: 8053574Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.Type: GrantFiled: July 16, 2008Date of Patent: November 8, 2011Assignee: Novartis AGInventors: Ian Bruce, Darren Mark Legrand, James Dale, Thomas Anthony Hunt
-
Patent number: 8008335Abstract: The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula (I).Type: GrantFiled: October 14, 2005Date of Patent: August 30, 2011Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Rustum S. Boyce, Yi Xia, Hongyan Guo, Kris G. Mendenhall, Annette O. Walter, Weibo Wang
-
Patent number: 7997510Abstract: In some embodiments a propulsion system includes a thrust chamber having an inside wall, an expansion nozzle mounted to the thrust chamber and having an interior and having an exterior, a main propellant injector mounted to the thrust chamber to inject a fluid in the interior of the thrust chamber, the fluid comprising oxidizer, fuel and internal film coolant, the internal film coolant ranging from about 1% to about 5% of the fluid, limited coolant tubing circumscribing the exterior of the expansion nozzle to circulate an external coolant, and an injector mounted to the expansion nozzle to inject the external coolant in the interior of the expansion nozzle, the external convective coolant about 2.5% of the fluid. The system operates at lower temperatures while having conventional amounts of thrust, in which the thrust chamber can be made of thin walls of lower cost conventional metals with simple coolant tube construction.Type: GrantFiled: July 24, 2007Date of Patent: August 16, 2011Inventors: Thomas Clayton Pavia, James Robert Grote
-
Patent number: 7998972Abstract: The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoloquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.Type: GrantFiled: May 20, 2003Date of Patent: August 16, 2011Assignee: Novartis AGInventors: Carlos Garcia-Echeverria, Hans-Georg Capraro, Pascal Furet
-
Patent number: 7994203Abstract: There are described pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.Type: GrantFiled: August 3, 2009Date of Patent: August 9, 2011Assignee: Novartis AGInventors: Ian Bruce, Andrew James Culshaw, Nicholas James Devereux, François Gessier, Jeffrey McKenna, James Neef, Helen Elizabeth Oakman